PRRUF
IMMUTEP LTD ORD by Immutep Ltd. (PRRUF)
$20
About IMMUTEP LTD ORD by Immutep Ltd. (PRRUF)
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Details
Daily high
$0.20
Daily low
$0.20
Price at open
--
52 Week High
$0.22
52 Week Low
$0.19
Market cap
297.0M
Dividend yield
0.00%
Volume
10,000
Avg. volume
650
P/E ratio
-7.42
IMMUTEP LTD ORD by Immutep Ltd. News
Details
Daily high
$0.20
Daily low
$0.20
Price at open
--
52 Week High
$0.22
52 Week Low
$0.19
Market cap
297.0M
Dividend yield
0.00%
Volume
10,000
Avg. volume
650
P/E ratio
-7.42